Anlon Healthcare MD, chairman, board of directors and AGM
NSE: AHCLBSE: 544497Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹24.35.
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,359 Cr1,681st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 46.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 30 Jul 2026
- 13.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 18.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 67,35,80547.9% delivered
Anlon Healthcare board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorPUNITKUMAR RAMESHBHAI RASADIA
- Company Secretary and Compliance OfficerAmita Chhaganbhai Pragada
6 directors3 independent2 executive1 non-executive
- PUNITKUMAR RAMESHBHAI RASADIA · Chairperson and managing directorExecutive · joined Nov 2023 · reappointed Jul 2024 · 1 listed board · 1 committee seat
- MEET ATULKUMAR VACHHANIExecutive · joined Nov 2023 · reappointed Jul 2024 · 1 listed board · 1 committee seat
- MAMATA PUNITKUMAR RASADIANon-executive · joined Jul 2024 · 1 listed board
- KRISHNA MURTY KANNEPALLIIndependent · joined Aug 2024 · 60 months as independent · 1 listed board · 1 as independent
- ANANDBHAI NATWERLAL KATKORIAIndependent · joined Aug 2024 · 60 months as independent · 1 listed board · 1 as independent · 2 committee seats
- KISHAN VINODKUMAR RAJAIndependent · joined Sep 2026 · 60 months as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- SHAILESH KANTILAL THAKKAR, left 9 Feb 2026: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 13 Aug 20266 of 6 present3 independent · 13 days in between
- 30 Jul 20266 of 6 present3 independent · 28 days in between
- 1 Jul 20266 of 6 present3 independent · 25 days in between
- 5 Jun 20266 of 6 present3 independent · 6 days in between
5 earlier meetings
- 29 May 20266 of 6 present3 independent · 31 days in between
- 27 Apr 20266 of 6 present3 independent · 10 days in between
- 16 Apr 20266 of 6 present3 independent · no day in between
- 15 Apr 20266 of 6 present3 independent · 10 days in between
- 4 Apr 20266 of 6 present3 independent
Audit Committee
Chair KRISHNA MURTY KANNEPALLI
ANANDBHAI NATWERLAL KATKORIA, PUNITKUMAR RAMESHBHAI RASADIA
- 13 Aug 20263 of 3 present2 independent · 13 days in between
- 30 Jul 20263 of 3 present2 independent · 61 days in between
- 29 May 20263 of 3 present2 independent · 42 days in between
- 16 Apr 20263 of 3 present2 independent
Nomination and remuneration committee
Chair KRISHNA MURTY KANNEPALLI
ANANDBHAI NATWERLAL KATKORIA, MAMATA PUNITKUMAR RASADIA
- 13 Aug 20263 of 3 present2 independent · 75 days in between
- 29 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair MAMATA PUNITKUMAR RASADIA
MEET ATULKUMAR VACHHANI, ANANDBHAI NATWERLAL KATKORIA
- 13 Aug 20263 of 3 present1 independent
Risk Management Committee
Chair PUNITKUMAR RAMESHBHAI RASADIA
MEET ATULKUMAR VACHHANI, KRISHNA MURTY KANNEPALLI
- 13 Aug 20263 of 3 present1 independent
Corporate Social Responsibility Committee
Chair PUNITKUMAR RAMESHBHAI RASADIA
MEET ATULKUMAR VACHHANI, ANANDBHAI NATWERLAL KATKORIA
- 13 Aug 20263 of 3 present1 independent
Internal Complaints Committee
Chair MAMATA PUNITKUMAR RASADIA
PUNITKUMAR RAMESHBHAI RASADIA, MEET ATULKUMAR VACHHANI
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- R V D & Co.Peer-review certificate valid to Jun 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Anlon Healthcare AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Anlon Healthcare share news and announcements
Annual general meeting, 5 Sep 2026
36,881 shareholders on the register on 28 Jun 2026; present: 2 promoters and 29 others; votes counted by KEYUR GHELANI / K. P. GHELANI & ASSOCIATES.The company's voting result (opens in a new tab)
TO RECEIVE, CONSIDER AND ADOPT THE AUDITED STANDALONE FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026 TOGETHER WITH THE REPORTS OF THE BOARD OF DIRECTORS AND AUDITORS THEREONMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
TO RECEIVE, CONSIDER AND ADOPT THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026 TOGETHER WITH THE REPORTS OF THE BOARD OF DIRECTORS AND AUDITORS THEREONMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
- TO APPOINT A DIRECTOR IN PLACE OF MR. PUNITKUMAR RAMESHBHAI RASADIA (DIN: 06696258) WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE- APPOINTMENTOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 0.99% · promoters 0.00% · institutions 48.35% · other public 0.05%
- TO APPOINT MR. KISHAN VINODKUMAR RAJA (DIN: 11522235) AS A NON-EXECUTIVE & INDEPENDENT DIRECTOROrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 5.67%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
- TO APPROVE REMUNERATION OF COST AUDITOR OF THE COMPANYOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
- ENHANCEMENT OF AUTHORISED SHARE CAPITALOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
- ALTERATION OF CAPITAL CLAUSE CONTAINED IN THE MEMORANDUM OF ASSOCIATIONSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
APPROVAL FOR ISSUANCE OF 8,58,83,617 EQUITY SHARES OF THE COMPANY ON PREFERENTIAL BASIS FOR CONSIDERATION OTHER THAN CASH TO THE SHAREHOLDERS OF APIQO ORGANICS PRIVATE LIMITED AND BIZOTIC LIFESCIENCE PRIVATE LIMITEDMoreLess
SpecialPromoters have an interest in it99.99% for0.01% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.25%
Turnout: all 0.99% · promoters 0.00% · institutions 48.35% · other public 0.05%
- MATERIAL RELATED PARTY TRANSACTIONS BETWEEN APIQO ORGANICS PRIVATE LIMITED AND THE COMPANYOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
- MATERIAL RELATED PARTY TRANSACTIONS BETWEEN BIZOTIC LIFESCIENCE PRIVATE LIMITED AND THE COMPANYOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
- MATERIAL RELATED PARTY TRANSACTIONS BETWEEN ANLON MEDICOS PRIVATE LIMITED (Formerly known as Remember India Health Links Private Limited) AND THE COMPANYOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 53.67% · promoters 100.00% · institutions 48.35% · other public 0.05%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 8 Apr 2026, 5 resolutions
11,205 shareholders on the register on 6 Mar 2026; votes counted by Mr. Keyur Ghelani / M/s. K. P. Ghelani and Associates.The company's voting result (opens in a new tab)
- To consider and approve the Sub-Division (Stock split) of every 1(One) Equity Share of face value of Rs.10.00/- each into 5 (Five) Equity Shares of face value of Rs.2/- eachOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 58.51% · promoters 100.00% · institutions 98.40% · other public 1.75%
- To consider and approve the alteration of Capital Clause of the Memorandum of Association of the Company subsequent to Sub-Division of Equity SharesSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 58.51% · promoters 100.00% · institutions 98.40% · other public 1.75%
- To consider and approve the Increase in Authorized Share CapitalOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 58.51% · promoters 100.00% · institutions 98.40% · other public 1.75%
- To consider and approve the Alteration of Capital Clause contained in the Memorandum of Association of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 58.51% · promoters 100.00% · institutions 98.40% · other public 1.75%
- To consider and approve Issue of Bonus SharesOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 58.51% · promoters 100.00% · institutions 98.40% · other public 1.75%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 7 Jan 2026, 1 resolution
11,732 shareholders on the register on 5 Dec 2025; votes counted by Mr. Keyur Ghelani / M/s. K. P. Ghelani and Associates.The company's voting result (opens in a new tab)
- To consider and approve the variation in one of the objects of the initial public offering (IPO) for proposed expansion through inorganic growth and further upgradationSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 57.29% · promoters 100.00% · institutions 90.18% · other public 0.49%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Stakes in unlisted companies
Reported in the filing for the quarter to Sep 2026.
- Unlisted stake boughtANLON MEDICARE PRIVATE LIMITEDSince 9 Jul 2026
55.00% bought in the quarter; holding 55.00%, from 0.00%
- Unlisted stake boughtANLON BIOLOGICS PRIVATE LIMITEDSince 10 Jul 2026
65.00% bought in the quarter; holding 65.00%, from 0.00%
- Unlisted stake boughtANLON HEALTHCARE NIGERIA LIMITEDSince 20 Sep 2026
90.00% bought in the quarter; holding 90.00%, from 0.00%
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Public IssuesSep 2025, checked by Crisil Ratings Limited | 121.03 | Funding capital expenditure requirements for the expansion of our Manufacturing Facility | 30.72 | 30.72 | Yes | Company proposed to vary the object in relation to the capital expenditure and proposed expansion and proposes to deploy/ utilize an amount of Rs. 2,332.69 lakhs out of Rs. 3,071.95 lakhs for such strategic acquisitions/ mergers/ buy-outs to grow inorganically, and further upgradation of the manufacturing facilitiesMoreLess |
| Public IssuesSep 2025, checked by Crisil Ratings Limited | 121.03 | Full or part repayment and/or pre-payment of certain outstanding secured borrowing (term loan) availed by our Company | 5.00 | 5.00 | Yes | Company proposed to vary the object in relation to the capital expenditure and proposed expansion and proposes to deploy/ utilize an amount of Rs. 2,332.69 lakhs out of Rs. 3,071.95 lakhs for such strategic acquisitions/ mergers/ buy-outs to grow inorganically, and further upgradation of the manufacturing facilitiesMoreLess |
| Public IssuesSep 2025, checked by Crisil Ratings Limited | 121.03 | Funding the Working capital requirement | 43.15 | 43.15 | Yes | Company proposed to vary the object in relation to the capital expenditure and proposed expansion and proposes to deploy/ utilize an amount of Rs. 2,332.69 lakhs out of Rs. 3,071.95 lakhs for such strategic acquisitions/ mergers/ buy-outs to grow inorganically, and further upgradation of the manufacturing facilitiesMoreLess |
| Public IssuesSep 2025, checked by Crisil Ratings Limited | 121.03 | Offer Expense | 14.29 | 14.29 | Yes | Company proposed to vary the object in relation to the capital expenditure and proposed expansion and proposes to deploy/ utilize an amount of Rs. 2,332.69 lakhs out of Rs. 3,071.95 lakhs for such strategic acquisitions/ mergers/ buy-outs to grow inorganically, and further upgradation of the manufacturing facilitiesMoreLess |
| Public IssuesSep 2025, checked by Crisil Ratings Limited | 121.03 | General Corporate Purpose | 27.87 | 27.87 | Yes | Company proposed to vary the object in relation to the capital expenditure and proposed expansion and proposes to deploy/ utilize an amount of Rs. 2,332.69 lakhs out of Rs. 3,071.95 lakhs for such strategic acquisitions/ mergers/ buy-outs to grow inorganically, and further upgradation of the manufacturing facilitiesMoreLess |